Back

Identification of a mimotope of a complex gp41 Human Immunodeficiency VIrus epitope related to a non-structural protein of Hepacivirus previously implicated in Kawasaki disease

Sojar, H.; Baron, S.; Hicar, M. D.

2024-06-28 immunology
10.1101/2024.06.26.600771 bioRxiv
Show abstract

BackgroundWe have previously isolated a highly mutated VH1-02 antibody termed group C 76-Q13-6F5 (6F5) that targets a conformational epitope on gp41. 6F5 has the capacity to mediate Ab dependent cell cytotoxicity (ADCC). When the VH1-02 group C 76 antibodies variable chain sequence was reverted to germline (76Canc), this still retained ADCC activity. Due to this ability for the 76Canc germline antibody to functionally target this epitope, we sought to identify a protein target for vaccine development. MethodsInitially, we interrogated peptide targeting by screening a microarray containing 29,127 linear peptides. Western blot and ELISAs were used to confirm binding and explore human serum targeting. Autoimmune targeting was further interrogated on a yeast-displayed human protein microarray. Results76Canc specifically recognized a number of acidic peptides. Meme analysis identified a peptide sequence similar to a non-structural protein of Hepacivirus previously implicated in Kawasaki disease (KD). Binding was confirmed to top peptides, including the Hepacivirus-related and KD-related peptide. On serum competitions studies using samples from children with KD compared to controls, targeting of this epitope showed no specific correlation to having KD. Human protein autoantigen screening was also reassuring. ConclusionsThis study identifies a peptide that can mimic the gp41 epitope targeted by 76C group antibodies (i.e. a mimotope). We show little risk of autoimmune targeting including any inflammation similar to KD, implying non-specific targeting of this peptide during KD. Development of such peptides as the basis for vaccination should proceed cautiously.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.4%
12.9%
2
Immunology
29 papers in training set
Top 0.1%
10.4%
3
Vaccine
189 papers in training set
Top 0.4%
8.7%
4
Vaccines
196 papers in training set
Top 0.2%
8.7%
5
PLOS ONE
4510 papers in training set
Top 30%
5.0%
6
PLOS Neglected Tropical Diseases
378 papers in training set
Top 2%
3.7%
7
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.3%
2.1%
50% of probability mass above
8
eBioMedicine
130 papers in training set
Top 0.9%
1.9%
9
The Lancet Rheumatology
11 papers in training set
Top 0.1%
1.7%
10
Journal of Virology
456 papers in training set
Top 2%
1.7%
11
Molecular Immunology
14 papers in training set
Top 0.2%
1.7%
12
Scientific Reports
3102 papers in training set
Top 56%
1.7%
13
Allergy
23 papers in training set
Top 0.3%
1.5%
14
Journal of Medical Virology
137 papers in training set
Top 2%
1.5%
15
Journal of Immunological Methods
24 papers in training set
Top 0.1%
1.4%
16
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.5%
1.3%
17
Clinical Immunology
21 papers in training set
Top 0.4%
1.0%
18
ImmunoInformatics
11 papers in training set
Top 0.2%
1.0%
19
Vaccine: X
19 papers in training set
Top 0.2%
1.0%
20
Journal of Clinical Microbiology
120 papers in training set
Top 1%
0.9%
21
Open Forum Infectious Diseases
134 papers in training set
Top 2%
0.9%
22
PLOS Pathogens
721 papers in training set
Top 8%
0.9%
23
Antibody Therapeutics
16 papers in training set
Top 0.4%
0.8%
24
Infection, Genetics and Evolution
43 papers in training set
Top 0.8%
0.8%
25
Genome Medicine
154 papers in training set
Top 7%
0.8%
26
Viruses
318 papers in training set
Top 5%
0.8%
27
Diagnostic Microbiology and Infectious Disease
21 papers in training set
Top 0.2%
0.8%
28
Clinical and Experimental Immunology
12 papers in training set
Top 0.1%
0.8%
29
Science
429 papers in training set
Top 20%
0.7%
30
Nucleic Acids Research
1128 papers in training set
Top 18%
0.7%